Member Info for RayPointer

It's particularly significant since Ugur Sahin (CEO of Biontech) is an admirer of Lindy's science

Genmab would only be interested in Glymabs and possibly also Avidimab.

I also suspect that they need to see some clinical results first before considering a platform deal.

Unless he is busy doing something else.

On the other side of the fence, Einstein used to work in a patent office.

He was only a "third class technical expert" though 🤣

https://www.historyonthenet.com/albert-einstein-and-the-patent-office

WTP

The development and trial related work is centred at the Oxford lab whilst Lindy and her team of researchers are based in Nottingham (Biodiscovery centre)

It could be that we are all the same person with many voices in the one head

Https://journals.sagepub.com/doi/full/10.1177/20563051231194584

See the general discussion at the end of this article:

"All three experiments consistently showed that displaying many emojis decreased message credibility and source trustworthiness."

😂

"Watching Val always makes me contemplate skiing as a pastime. Something about the share price graph reminding me of the slopes."

Definitely a black run 😀

It may not be purely down to money.

It is looking that Modi1 plus CPIs is the way to go judging from initial results.

So this would place the emphasis on the cancers for which CPIs have already been approved as a treatment.

Also 3 million share options at 17.5p

Maybe Mrs Ruck agrees 😂

Ruck

I suspect that the computer algorithms employed by Scancell are very useful and constantly improved upon. This will be a specialised program that attempts to predict the best antigens to target given the shape of a protein.

I suspect that AI, as it stands currently, is pretty useless to Scancell.

See you at the interview 😂

Back in 2019, Scancell were already using computer algorithms to identify Moditope epitopes:

https://www.lse.co.uk/rns/SCLP/posters-at-cancer-immunotherapy-conference-ugf28n9g9vylnum.html

One of the six posters at a conference in Paris:

"Improving selection criteria for post translationally modified CD4 epitopes using computer algorithms" by Scancell and Nottingham University"

To clarify Modi-1 is one vaccine.

The same epitopes are targeted whatever the cancer type that is being treated.

It's more likely that he is referring to future Moditope vaccines and Mod1-2 in particular.

The salesman for that Allegro has just received a LOI to purchase from a customer called Ken.

PM in a post yesterday you said:

"TRX were chosen over large pharma because they specialise in this field."

You seem to imply that Val had offers from large pharma but turned them down in favour of a LOI from TRX. Either that or Val did not pursue a deal with a large pharma.

Do you honestly believe that?

Letter of Intent number 3 from TheoremRx 🤣

Shareswotter

https://awaken.com/2024/12/8-vehicle-manufacturers-working-on-hydrogen-fuel-cell-cars/

This is a recent list of car manufacturers currently producing hydrogen powered cars. No mention of sales volumes though.

There's a relevant comment on the Calculus VCT website:

"Negative investor sentiment towards the LSE Alternative Investment Market (AIM) remains a challenge for the quoted companies held within the Company portfolio. In the same period as the Company’s FYE, the FTSE AIM All Share declined by -13.6%, highlighting

the supressed sentiment. Lack of liquidity and the higher risk profile of AIM means a large majority of the market constituents remain considerably undervalued. Arecor Therapeutics plc, one of the Company’s healthcare/ drug discovery portfolio companies, is now being held at a market value which is £0.46m lower that its closing value for the FYE 2023 notwithstanding considerable progress in the development of its portfolio of treatments. Other listed companies, including Destiny Pharma plc and Scancell Holdings plc lost an aggregate of £0.27m, again despite considerable scientific progress."

I certainly share this view of Calculus.

I think angelo has been on the martini 😄